Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gideon M Blumenthal

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
The Oncologist|April 17, 2020
Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer DrugsJanice Kim, Abhilasha Nair, Patricia Keegan, et al.
The Oncologist|May 29, 2014
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutationsSean Khozin, Gideon M Blumenthal, Xiaoping Jiang, et al.
Clinical Chemistry|February 25, 2020
Development, Validation, and Regulatory Considerations for a Liquid Biopsy TestDana W Y Tsui, Gideon M Blumenthal, Reena Philip, et al.
Clinical Pharmacology and Therapeutics|September 14, 2017
A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple MyelomaG K Raju, Karthik Gurumurthi, Reuben Domike, et al.
The Oncologist|March 13, 2020
An Analysis of Recent FDA Oncology Scientific PublicationsJulie A Schneider, Andrew C Miklos, James Onken, et al.
JAMA Oncology|June 16, 2017
Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysisGideon M Blumenthal, Lijun Zhang, Hui Zhang, et al.
Plos One|March 1, 2019
Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancerTristan M Sissung, Arun Rajan, Gideon M Blumenthal, et al.
Clinical Trials (London, England)|March 19, 2019
Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directionsBellinda L King-Kallimanis, Lynn J Howie, Jessica K Roydhouse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2019
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary SyndromeYvette L Kasamon, Haiyan Chen, R Angelo de Claro, et al.
The Oncologist|March 28, 2019
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell LymphomaNicholas C Richardson, Yvette L Kasamon, Haiyan Chen, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
The Oncologist|April 17, 2020
Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer DrugsJanice Kim, Abhilasha Nair, Patricia Keegan, et al.
The Oncologist|May 29, 2014
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutationsSean Khozin, Gideon M Blumenthal, Xiaoping Jiang, et al.
Clinical Chemistry|February 25, 2020
Development, Validation, and Regulatory Considerations for a Liquid Biopsy TestDana W Y Tsui, Gideon M Blumenthal, Reena Philip, et al.
Clinical Pharmacology and Therapeutics|September 14, 2017
A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple MyelomaG K Raju, Karthik Gurumurthi, Reuben Domike, et al.
The Oncologist|March 13, 2020
An Analysis of Recent FDA Oncology Scientific PublicationsJulie A Schneider, Andrew C Miklos, James Onken, et al.
JAMA Oncology|June 16, 2017
Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysisGideon M Blumenthal, Lijun Zhang, Hui Zhang, et al.
Plos One|March 1, 2019
Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancerTristan M Sissung, Arun Rajan, Gideon M Blumenthal, et al.
Clinical Trials (London, England)|March 19, 2019
Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directionsBellinda L King-Kallimanis, Lynn J Howie, Jessica K Roydhouse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2019
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary SyndromeYvette L Kasamon, Haiyan Chen, R Angelo de Claro, et al.
The Oncologist|March 28, 2019
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell LymphomaNicholas C Richardson, Yvette L Kasamon, Haiyan Chen, et al.
Pageof 9